Deepa Jeyakumar
Chao Family Comprehensive Cancer Center
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Deepa Jeyakumar as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-11 16:32 UTC. Open this list on ClinicalTrials.gov
- Ph2NCT04231851 · CPX-351 and Glasdegib for Newly Diagnosed Acute Myelogenous Leukemia With MDS Related Changes or Therapy-related Acute Myeloid LeukemiaUniversity of California, Irvine · active not recruiting · Acute Myelogenous Leukemia (AML) Due to Therapy, Acute Myeloid Leukemia With Myelodysplasia-Related Changes · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-11 16:32 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-11 16:32 UTC. The ranking covers the 200 most relevant of 9 PubMed records, and a shared surname and initials can bring in a namesake. All 9 on PubMed
- 731 citationsRCR 37.6
- Blinatumomab for MRD-Negative Acute Lymphoblastic Leukemia in Adults.N Engl J Med · 2024258 citationsRCR 31.2
- Magrolimab in Combination With Azacitidine in Patients With Higher-Risk Myelodysplastic Syndromes: Final Results of a Phase Ib Study.J Clin Oncol · 2023182 citationsRCR 15.3
- 135 citationsRCR 10.8
- 32 citationsRCR 2.8
- A phase 1b study of venetoclax and alvocidib in patients with relapsed/refractory acute myeloid leukemia.Hematol Oncol · 202318 citationsRCR 1.8
- A phase 1 study of IO-202, an anti-LILRB4 antibody, in chronic myelomonocytic leukemia and acute myeloid leukemia.Blood Neoplasia · 20255 citationsRCR 1.0
- CPX-351 plus gemtuzumab ozogamicin for relapsed/refractory acute myelogenous leukemia: a University of California Hematologic Malignancies Consortium trial.Leuk Lymphoma · 20253 citationsRCR 0.7
- 1 citationsRCR 0.2